Rituximab Therapy in Pemphigus and Other Autoantibody-mediated Diseases

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2017 Feb 11

PMID 28184292

Citations 10

Authors

Nina A Ran

Aimee S Payne

Affiliations

Soon will be listed here.

Abstract

Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases.

Citing Articles

Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris.

Raviv T, Pevzner K, Barzilai A, Pavlotsky F, Baum S Acta Derm Venereol. 2025; 105:adv27140.

PMID: 39749385 PMC: 11697143. DOI: 10.2340/actadv.v105.27140.

Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases.

Popa L, Dumitras I, Giurcaneanu C, Berghi O, Radaschin D, Vivisenco C Life (Basel). 2024; 14(10).

PMID: 39459523 PMC: 11508628. DOI: 10.3390/life14101223.

Restoring immune tolerance in pemphigus vulgaris.

Ahmed A, Kalesinskas M, Kaveri S Proc Natl Acad Sci U S A. 2024; 121(5):e2317762121.

PMID: 38261616 PMC: 10835025. DOI: 10.1073/pnas.2317762121.

Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis.

Seals M, Moran M, Leavenworth J, Leavenworth J Front Immunol. 2022; 13:900117.

PMID: 35784370 PMC: 9243362. DOI: 10.3389/fimmu.2022.900117.

Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication.

Jiang Y, Song J, Wang N, Yuan D, Feng L, Qu H Cancer Biol Ther. 2020; 21(11):1060-1066.

PMID: 33121338 PMC: 7678941. DOI: 10.1080/15384047.2020.1832017.

References

Shulman N, Marder V, WEINRACH R . Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965; 124(2):499-542. DOI: 10.1111/j.1749-6632.1965.tb18984.x. View

Arnold D, Heddle N, Carruthers J, Cook D, Crowther M, Meyer R . A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012; 119(6):1356-62. DOI: 10.1182/blood-2011-08-374777. View

Rock B, Labib R, Diaz L . Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest. 1990; 85(1):296-9. PMC: 296418. DOI: 10.1172/JCI114426. View

Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K . Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007; 13(1):128-32. DOI: 10.1177/1352458506071174. View

Schmidt E, Obe K, Brocker E, Zillikens D . Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000; 136(2):174-8. DOI: 10.1001/archderm.136.2.174. View

Wasserstrum N, Laros Jr R . Transplacental transmission of pemphigus. JAMA. 1983; 249(11):1480-2. View

Weinshenker B, Wingerchuk D, Vukusic S, Linbo L, Pittock S, Lucchinetti C . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59(3):566-9. DOI: 10.1002/ana.20770. View

Zoppi M, Oppliger R, ALTHAUS U, Nydegger U . Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed. 1993; 20(1-2):19-22. DOI: 10.1159/000222800. View

Amagai M, Hashimoto T, Shimizu N, Nishikawa T . Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest. 1994; 94(1):59-67. PMC: 296282. DOI: 10.1172/JCI117349. View

10.

Sadler E, Schafleitner B, Lanschuetzer C, Laimer M, Pohla-Gubo G, Hametner R . Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007; 157(2):417-9. DOI: 10.1111/j.1365-2133.2007.08048.x. View

11.

van Beek N, Rentzsch K, Probst C, Komorowski L, Kasperkiewicz M, Fechner K . Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis. 2012; 7:49. PMC: 3533694. DOI: 10.1186/1750-1172-7-49. View

12.

Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T . Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009; 386(4):623-7. DOI: 10.1016/j.bbrc.2009.06.085. View

13.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

14.

Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet A . Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2014; 14(4):304-13. DOI: 10.1016/j.autrev.2014.11.014. View

15.

Lennon V, Kryzer T, Pittock S, Verkman A, Hinson S . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4):473-7. PMC: 2212860. DOI: 10.1084/jem.20050304. View

16.

Vincent A, Bowen J, Newsom-Davis J, McConville J . Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2003; 2(2):99-106. DOI: 10.1016/s1474-4422(03)00306-5. View

17.

Hammers C, Chen J, Lin C, Kacir S, Siegel D, Payne A . Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. 2014; 135(3):742-749. PMC: 4294994. DOI: 10.1038/jid.2014.291. View

18.

Woodley D, Ram R, Doostan A, Bandyopadhyay P, Huang Y, Remington J . Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol. 2006; 126(6):1323-30. DOI: 10.1038/sj.jid.5700254. View

19.

Sanders J, Jeffreys J, Depraetere H, Evans M, Richards T, Kiddie A . Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. Thyroid. 2004; 14(8):560-70. DOI: 10.1089/1050725041692918. View

20.

Rieger M, Mannucci P, Kremer Hovinga J, Herzog A, Gerstenbauer G, Konetschny C . ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106(4):1262-7. DOI: 10.1182/blood-2004-11-4490. View